Introduction
In Canada, cardiovascular disease (CVD) is the second leading cause of mortality after cancer (1) . Many risk factors contribute to increase the risk of developing CVD. Among them, plasma triglyceride concentrations (TG) have been debated about whether they should be considered as an independent CVD risk factor. A review by Morisson et al. (2) , indicated that plasma TG concentrations are an independent risk factor of coronary events in individuals without previous history of coronary heart disease (CHD). Plasma TG concentrations was the parameter of the metabolic syndrome the most strongly and independently associated with myocardial infarction and stroke (3) . However, a recent meta-analysis has demonstrated no independent association between plasma TG concentrations and CVD risk (4) . Still, the presence of high plasma TG concentrations is an important biomarker indicating alterations of lipid metabolism.
Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been proven as an effective way to reduce plasma TG concentrations (5) . However, a large inter-individual variability has been observed in plasma TG concentrations response following an n-3 PUFA supplementation (6) (7) (8) . A decrease in de novo lipogenesis is one of a few pathways which could explain the n-3 PUFA plasma TG lowering effects. Lipogenesis is strongly regulated by the transcription factor Sterol regulatory element binding transcription factor 1 (SREBF1) (9). N-3 PUFA decrease the expression of SREBF1 (10, 11). SREBF1 regulates the activity of several lipogenic genes such as ATP citrate lyase (ACLY) and acetyl-CoA carboxylase alpha (ACACA). ACLY is the primary enzyme responsible for the synthesis of acetyl-CoA in the cytosol (12). Acetyl-CoA may then be transformed by by guest, on October 14, 2017 www.jlr.org Downloaded from few polymorphisms within these genes have been studied. SREBF1, gly952gly (rs2297508), has been associated with obesity, type 2 diabetes and serum lipids (14- 16) whereas a few SNPs within ACACA gene (rs1266175 and rs2229416) were associated with plasma TG concentrations after the intake of certain antipsychotic drugs (17) . The effects of SNPs within these genes on plasma TG concentrations have never been studied in the context of an n-3 PUFA supplementation. Therefore, the aim of the present study was to examine the associations between polymorphisms in genes involved in lipogenesis pathway and the plasma TG response following a marine n-3 PUFA supplementation.
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Methods
Subjects
A total of 254 unrelated subjects were recruited to participate in this clinical trial from the greater Quebec City metropolitan area between September 2009 and December 2011 through advertisements in local newspapers as well as by electronic messages sent to university students/employees. It was determined that a group of 152 participants was sufficient to provide an 80% probability and a 5% significance level of detecting an anticipated difference of 0.25 mmol/L in plasma triglycerides concentrations after 6 weeks of fish oil supplementation with a genetic variation occurring in a relatively low frequency (5%) of the population. To be eligible, subjects had to be non-smokers and free of any thyroid or metabolic disorders requiring treatment such as diabetes, hypertension, severe dyslipidemia, and coronary heart disease. Participants had to be aged between 18 and 50 years old and with a body mass index (BMI) between 25 and 40 Kg/m 2 . The subjects who had taken n-3 PUFA supplements during the six months preceding the study were excluded. A total of 210 subjects completed the n-3 PUFA supplementation period.
However, plasma TG concentrations were available for 208 participants, thus the analyses were conducted on 208 participants. The experimental protocol was approved by the ethics committees of Laval University Hospital Research Center and Laval
University. This clinical trial was registered at clinicaltrials.gov (NCT01343342).
Informed written consent was obtained from all the study subjects.
Study design and diets
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Subjects followed a run-in period of 2 weeks. Individual dietary instructions were given by a trained dietitian to achieve the recommendations from Canada's Food Guide.
Subjects were asked to follow these dietary recommendations and maintain their body weight stable throughout the research protocol. Some specifications were given regarding the n-3 PUFA dietary intakes: not to exceed two fish or seafood servings per week, prefer white flesh fishes instead of fatty fishes (examples were given) and avoid enriched n-3
PUFA dietary products such as some milks, juices, breads and eggs. Subjects were also asked to limit their alcohol consumption during the protocol: two regular drinks per week were allowed. In addition, subjects were not allowed to take n-3 PUFA supplements (such as flaxseed), vitamins or any natural health products during the protocol.
After the 2-week run-in period, each participant received a bottle containing n-3 PUFA capsules for the next 6 weeks. They were instructed to take five capsules (1 g of fish oil/capsule) per day (Ocean Nutrition, Nova Scotia, Canada), providing a total of 5 g of fish oil (1.9-2.2g EPA and 1.1 g DHA) per day. Capsules were provided in sufficient quantity for 6 weeks. Compliance was assessed from the return of bottles and by measuring plasma phospholipid fatty acid composition. Subjects were asked to report any deviation during the study protocol and to write down their alcohol and fish consumption as well as any side effects.
A validated food-frequency questionnaire (FFQ) was administrated to each participant before the run-in period by a trained registered dietitian (18 
Anthropometric measurements
Body weight, height, and waist girth were measured according to the procedures recommended by the Airlie Conference (19) and were taken before the run-in period, as well as before and after the n-3 PUFA supplementation. BMI was calculated as weight per meter squared (Kg/m 2 ).
Biochemical parameters
The morning after a 12-hour overnight fast and 48-h alcohol abstinence, blood samples were collected from an antecubital vein into vacutainer tubes containing EDTA. Blood samples were used to identify individuals with metabolic disorders, which were excluded.
Plasma was separated by centrifugation (2500 x g for 10 minutes at 4°C), samples were aliquoted and frozen for subsequent analyses. Plasma total cholesterol (total-C) and plasma TG concentrations were measured using enzymatic assays (20, 21) . Infranatant (d >1.006 g/ml) with heparin-manganese chloride was used to precipitate VLDL and LDL and then determine HDL cholesterol concentrations (HDL-C) (22) . The equation of
Friedewald was used to estimate LDL-cholesterol concentrations (LDL-C) (23) . Non-HDL-C was calculated by subtracting HDL-C from total-C. Plasma apoB-100 concentrations were measured by the rocket immunoelectrophoretic method of Laurell, as previously described (24) .
Fatty acid composition of plasma phospholipids
Briefly, plasma lipids were extracted with chloroform:methanol (2:1, by volume)
according to a modified Folch method (25) . Total PL were separated by thin layer chromatography using a combination of isopropyl ether and acetic acid and fatty acids of isolated PL were then methylated. Capillary gas chromatography was then used to obtain FA profiles. The technique used for plasma analyses has been previously validated (26) . 
SNPs selection and genotyping
SNPs
Statistical analyses
Hardy-Weinberg equilibrium was tested with the ALLELE procedure of SAS version 9.3 using Fisher's exact test (P<0.01). When the genotype frequency for homozygotes individuals of the minor allele was <5%, carriers (heterozygotes and homozygotes individuals) of the minor allele were grouped.
Variables non-normally distributed were logarithmically transformed. To examine the difference between responders and non-responders for the plasma TG response, two groups were created. The responders group included individuals who decreased their plasma TG concentrations after the supplementation period (relative change in plasma TG < 0%). The non-responders group included individuals who did not change their plasma TG concentrations or even increased them (relative change in plasma TG ≥ 0%).
Pre-supplementation and the relative change in the descriptive characteristics of the participants were compared between the responders and non-responders with an ANOVA including age, sex and BMI (except for BMI and waist circumference variables).
In order to verify the SNPs which were associated with the relative change in plasma TG concentrations, the GLM procedure of SAS was used and age, sex and BMI were included as confounding variables. To take into account the effects of multiple testing the simpleM procedure described by Gao et al. 
Results
Descriptive characteristics of the study population
Descriptive characteristics of the study participants are presented in Table 1 . Briefly, mean BMI was slightly over 25 Kg/m 2 and blood lipids were around normal values (33).
Descriptive characteristics of the study participants according to plasma TG response (responders vs non-responders), are shown in Table 2 . Before the supplementation, nonresponders had higher HDL-C concentrations and lower plasma TG concentrations than responders. After the supplementation, non-responders increased slightly more their BMI than responders. Non-responders increased their total-C and plasma TG concentrations and decreased their HDL-C while the opposite was observed for responders. These results are concordant with our previous results for a subset of 12 selected participants from this cohort (34).
TSNPs and baseline characteristics according to genotypes
The compliance rate for the fish oil supplementation was 94.41%±8.33%. The responders had a compliance rate of 93.98%±8.85% (n=148) and for the non-responders the compliance rate was 95.48%±6.71% (n=60) (p=0.17). No differences were observed in fatty acid incorporation into plasma phospholipids (total n-3 PUFA, EPA and DHA) between responders and non-responders (data not shown). The selected SNPs are presented in Table 3 . All SNPs were in Hardy-Weinberg equilibrium. In Figure 1 (A to C), LD plot are presented. Briefly, three tSNPs covered 100% of the known genetic variability within SREBF1 gene, three tSNPs covered 88% for ACLY and eight tSNPs covered 85% for ACACA.
Age, sex and baseline BMI did not differ by genotypes except for rs4925118 (SREBF1)
for age, and rs12953299 (SREBF1) and rs1266175 (ACACA) for sex (p=0.01, p=0.01 and p=0.02, respectively). C/C homozygotes of rs4925118 (SREBF1) were slightly older than carriers of the rare allele (data not shown). A greater proportion of men were A/A homozygotes for rs12953299 (SREBF1) and G/G homozygotes for rs1266175 (63% for both). Genotype frequencies according to the plasma TG response group seemed to differ only for rs8071753 (ACLY) (p=0.02) and trends were observed for three tSNPs within ACACA gene (rs2921368, rs1714987 and rs3815059) ( Table 4) .
Associations between tSNPs and baseline plasma TG levels
The SNP rs1714987 (ACACA) seemed associated with pre-supplementation plasma TG concentrations (p=0.006) (adjusted for age, sex and BMI). Carriers of the G allele (n=69) seemed to have higher baseline plasma TG concentrations than C/C homozygotes (n=139) (1.32±0.58 mmol/L compared to 1.15±0.65 mmol/L).
Association between tSNPs and the plasma TG relative change
As presented in then be mobilized in the cytosol by lipolysis followed by re-esterification through a delayed pathway also contributing to VLDL-TG production (38, 39).
As described earlier, n-3 PUFA consumption induces a decrease in de novo lipogenesis mediated by SREBF1 gene (9-11, 40). In the literature, two SNPs within SREBF1 gene 
